anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To provide a pharmaceutical composition which has cure effect on lung cancer and alleviation of side effects to patients, and to provide a preparation method thereof.SOLUTION: An inhalation type pharmaceutical composition for lung cancer contains a first gas and atomization agent. The first gas contains hydrogen. The gas volume concentration of hydrogen in the inhalation type pharmaceutical composition is between 2 and 96%. The atomization agent is cisplatin, docetaxel, etoposide, gefitinib, erlotinib, or any combination thereof. The inhalation type pharmaceutical composition can increase absorption effect of the agent for a patient by using the atomization agent while being able to remove the harmful radical in the patient&#39;s body through use of hydrogen. Simultaneously, the side effect to a user can be indirectly reduced by using a small amount of a liquid evaporation agent.
1381178 1 -(Cinnamylideneamino)-3-(benzylideneamino)-guanidines MERCK &amp; CO Inc 13 Nov 1972 [19 Nov 1971] 52373/72 Heading C2C [Also in Division A5] Novel compounds (I) and their acid addition salts in which R 1  and R 11  are hydrogen, halogen, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, acetyl carbamoyl, cyano, methylsulphonyl, methylsulphonyl carbomethoxy or dimethylaminosulphonyl, R 2  and R 12  are hydrogen, halogen or nitro, R 3  and R 13  are hydrogen or halogen with the proviso that at least one of the ring substituents is other than hydrogen, R 4  and R 5  are hydrogen, halogen or C 1-5  alkyl, R 6  to R 9  are hydrogen or C 1-5  alkyl and R 10  is hydrogen, C 1-5  alkyl or C 1-5  alkanoyl are prepared by reacting an appropriately substituted 3-amino-1-cinnamylidene amino guanidine with an appropriately substituted benzaldehyde or alkylphenyl ketone or by the corresponding reaction of a 1-amino-3-benzylideneamino-guanidine with a cinnamaldehyde or alkylstyryl ketone. Compounds (I) in which R 7  and/or R 8  are C 1-5  alkyl and R 10  is hydrogen are prepared by reaction of a cyanamide (4) with the appropriate benzaldehyde hydrazone or alkylhydrazone (7) Compounds (I) in which R 10  is C 1-5  alkyl are prepared by reaction of a compound (11) with an alkyl-amine R 10 :NH 2  at an elevated temperature and under a slight superatmospheric pressure. Compounds (1) in which R 10  is C 1-5  alkanoyl are prepared by reacting the corresponding compound (1) in which R 10  is hydrogen with a C 1-5  alkanoic acid anhydride. Compound (4) is prepared by reacting a cinnamaldehyde or alkyl-styryl ketone with a hydrazine or alkylhydrazine to produce a hydrazone or alkylhydrazone (3) which is reacted with a slight excess of Br-CN in the presence of a weak base. Compound (7) is prepared by reaction of benzaldehyde or methylalkylketone with a hydrazine or alkylhydrazine. Compound (11) is prepared by treatment of a cinnamaldehyde or alkylstyryl ketone with thiocarbohydrazide at an elevated temperature in an alkanol to form a thiocarbohydrazone (9) which is reacted with a benzaldehyde or alkyl phenyl ketone to produce compound (10) which is reacted with methyl iodide in the presence of an alkali metal methoxide. Compounds (I) are coccidiostats and form with a suitable carrier an anti-coccidial composition which may be in the form of an animal feed drinking-water, a water-soluble powder or an animal feed supplement. The composition may contain a second coccidiostat selected from amprolium, nicarbazin, ethopobate or 3,5-dinitro-o-toluamide, vitamins, antibiotics, growth promotants or anti-viral agents.
PROBLEM TO BE SOLVED: To obtain a treated powder excellent in water repellency and dispersibility and a powdery cosmetic material contg. no oil by coating the surface of a powder with a silicone compd. having SiH groups and adding an SiH-reactive compd. to the parts of unreacted SiH groups of the silicone compd. in a specified density. SOLUTION: At least one powder having a particle size of 10 μm or lower and selected from among org. and inorg. pigments, metal oxides and hydroxides, mica, pearlescent materials, metals, etc., is used. It may be in the form of agglomerates or moldings. A superfine powder having a particle size of 0.02 μm or lower can be modified, too. Among silicone oils, silicone resins, silicon waxes, etc., a compd. represented by the formula (R&lt;1&gt; to R&lt;3&gt; are each H or a hydrocarbon group optionally halogenated; R&lt;4&gt; to R&lt;6&gt; are each H, etc.; a is 1 or higher; b is 0, 1, or higher; c is O or 2 provided 3&lt;=a+b+c&lt;=10,000; and there is at least one SiH group) is suitable as the silicone compd. An SiH- reactive compd. in an amt. of 100 μmol (based on 1 g of the powder) is added to the silicone compd.
PURPOSE:To obtain a natural calcium preparation containing hard capsule high in opacity, free from surface roughness by mixing a natural calcium fine powder having a specific particle diameter with gelatin. CONSTITUTION:The natural calcium fine powder &lt;=3mum in average particle diameter is obtained by dry-pulverizing by such as a Jet-O-Mizer or wet pulverizing by such as a colloid mill the natural calcium preparation mainly containing calcium carbonate obtained by calcining a natural raw material such as ox bone, oyster shell. After the calcium fine powder is made into an uniform dispersed solution with a dispersion medium by a homogenizer, 0.5-30wt.% natural calcium preparation is added into a gelatin aq. solution to give a gelatin aq. solution for producing the capsule. The hard capsule is produced by using the gelatin aq. solution by a conventional method of dipping method with hard capsule forming machine.
The invention comprises aza-bicycloalkyl-(N)-alkylguanidines of the general formula: &lt;FORM:0910427/IV (b)/1&gt; and their acyl derivatives, quaternary ammonium compounds and acid addition salts (including ascorbates), in which A stands for a 1-5 membered hydrocarbon chain which may also contain a double bond or be interrupted by a nitrogen atom which may be unsubstituted or substituted by an alkyl or aralkyl group, m represents any one of the numbers from 0 to 6, m1 any one of the numbers from 1 to 7, n and n1 any one of the numbers from 0 to 3. R and R1 stand for hydrogen atoms or C1-7-alkyl groups and G for a guanido group, with the proviso that CmH2m separates the bridgehead atoms by at most 2 carbon atoms, and in which &lt;FORM:0910427/IV (b)/2&gt; when A forms a 3-5 membered isocyclic ring with the bridge members and &lt;FORM:0910427/IV (b)/3&gt; when A forms a 4-membered azacyclic ring with the bridge members, and the preparation thereof by reacting an aza - bicycloalkyl - (N) - alkylamine corresponding to the above general formula but wherein G represents a primary or secondary amino group with S-methylthiourea or a mineral acid addition salt thereof. Acyl derivatives may be prepared from mono or dicarboxylic acids or sulphonic acids which may contain further substituents. Quaternary ammonium salts are preferably prepared from esters of lower alkanols or aralkanols.  The guanidines of the above general formula are useful as antihypertensive agents, and pharmaceutical compositions comprise the said compounds in admixture or in conjunction with an inert carrier suitable for enteral or parenteral administration.  The compositions may contain other therapeutically useful substances, and may be in the form of tablets, dragees, capsules, solutions, suspensions or emulsions.  Specification 910,428 is referred to.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing a dihydroquinoxalin-2-on derivative, which does not require many steps and is environmentally friendly, to provide a new dihydroquinoxalin-2-on derivative, and to provide a therapeutic agent for cancer.  &lt;P&gt;SOLUTION: The method for producing the dihydroquinoxalin-2-on derivative comprises a one-pot cyclization reaction between a (heterocyclic) aromatic compound having a halogen and an amino group as neighboring substituents, e.g. a 2-haloaniline derivative, and an α-amino acid derivative. Preferably, a copper catalyst, a base and an aprotic polar solvent are used. The derivative may be an optically active substance. The therapeutic agent for cancer comprises the dihydroquinoxalin-2-on derivative as an active ingredient and is particularly effective for treating human uterine cervical cancer.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
Upper extremity functions are of great importance, especially activities of daily living. There are opinions that the impairment of the upper extremity in scleroderma is greater than that of the lower extremity and affects the functional status of individuals more. This activity limitation is related to many activities of daily living, including unsupported upper limb movements that lead to dyspnea and fatigue in patients with cardiopulmonary disease. Therefore, determining the strength, endurance and exercise capacity of the upper extremities is an important issue in scleroderma management. One of the tests that serves this purpose is the 6PBRT, which has been found to be valid and reliable in patients with chronic obstructive pulmonary disease and asthma.

It was planned as a non-interventional reliability study. The study will investigate the validity and reliability of 6PBRT in patients with scleroderma. In this context, a 1-hour rest break will be given after the first test. Dyspnea and fatigue will be assessed using the Borg scale and muscle oxygenation, heart rate and blood pressure will be recorded before and after 6PBRT. After the 1-hour rest period, the second trial of 6PBRT will be performed. The level of dyspnea and fatigue and initial values of heart rate will be checked before the second trial to ensure that patients are stable. All assessments will be performed by the same physiotherapist. In addition, participants will be assessed for respiratory muscle strength, upper limb muscle strength and muscle oxidation during the performance test.

The smallest sample size of the study was 40 subjects with a correlation coefficient of 0.95 between the two tests and 90% power at 95% confidence interval. 50 subjects are aimed to be recruited against a 20% drop-out risk. Shapiro-Wilk test and histogram plots will be used to check the normality of the data. Demographic and clinical characteristics of the participants will be reported using descriptive statistics. Two-way random effects and absolute agreement methods and intraclass correlation coefficient (ICC) will be used to assess test-retest reliability. Reliability strength will be interpreted as excellent for an ICC value \&gt;0.90. The 95% Confidence Interval (95% CI) will be calculated to investigate measurement variability.
PURPOSE:The titled sedative containing a water-soluble derivative of acetylsalicylic acid as an active ingredient. CONSTITUTION:A analgesic and sedative in emergence recovery from anesthesia containing a water-soluble derivative of acetylsalicylic acid, e.g. acetylsalicylic acid DL-lysine salt, as an active ingredient. The above-mentioned analgesic and sedative is administered 10-60min before emergence recovery in performing operation while in systemic anesthesia. The dosage form is preferably injection and the above-mentioned active ingredient is dissolved in distilled water for injection, physiological saline solution, etc., in 5-20w/v%, preferably 10w/v% concentration and prepared in use. The dose thereof is 100-1,000mg/time expressed in terms of the acetylsalicylic acid and intravenously administered. EFFECT:The degree of patient&#39;s rest is excellent without acting on the consciousness in emergence recovery. Since the analgesic and sedative is injection, administration is very readily carried out without inducing gastrointestinal injury as in the case of solution for internal use.
The FtsH protein, which was originally identified as an hflB mutation, is highly conserved in all organisms and is the only known essential protease in E. coli. A number of protein substrates for the E. coli FtsH were identified, which include, inter alia, the heat shock σ32 factor, the phage μCII, CIII and Xis proteins. The present invention relates to a substance targeted to the C-terminal domain of FtsH which domain is essential for the biological function thereof, said substance being capable of competing or interacting with said domain with a naturally occurring substrate thereof and thus of inhibiting FtsH biological activity. As disclosed herein, the present invention relates in particular to inhibitors of FtsH which are derived from the CIII protein. Furthermore, the invention relates to a DNA sequence encoding a substance in accordance with the invention. The DNA sequence may be inserted into a suitable vehicle to form a DNA construct which is also in accordance with the invention and be transformed into target cells that will result in the alteration of the cell&#39;s behaviour. The substance, DNA sequence or DNA construct of the invention may be employed in different manners, for example, as antibiotics.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a use relating to metabolism of blood iron as a new use of Camellia sinensis polyphenols obtained by extracting Camellia sinensis.  &lt;P&gt;SOLUTION: This prophylactic/therapeutic agent against excess iron caused hepatopathy comprises ≥50% total of Camellia sinensis polyphenols, preferably (-)-epicatechin gallate and (-)-epigallocatechin gallate as an active ingredient. In the case of high blood iron concentration, the oral administration of the agent removes excess blood iron to reduce blood iron concentration. In the case of relatively low blood iron concentration, administration of the agent with iron has stabilization action (control action) of promoting iron absorption and controlling reduction in blood iron concentration. Furthermore, in the operation, the agent has not a great influence on the number of erythrocytes and hemoglobin concentration.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
PROBLEM TO BE SOLVED: To obtain a medicine, comprising a heterocyclic derivative as an active ingredient, having excellent suppressing actions on neuron necrosis and useful as a therapeutic agent for cerebral angiopathy. SOLUTION: This medicine comprises a compound of formula I [R&lt;1&gt; is an aryl or an aromatic heterocyclic ring; R&lt;2&gt; is H, an alkyl, an alkenyl, a cycloalkyl, an alkoxy, etc.; R&lt;3&gt; and R&lt;4&gt; are each H, an alkyl or are bonded to adjacent N to denote a 5- to a 7-membered ring cyclic amino; A is a 2-10C alkylene; W is O, S or (CH)n ; (n) is 0-2; X, Y and Z are each CH, N, etc.] or its salt or a solvate thereof as an active ingredient. 4-(4-Fluorophenyl)-2-methyl-6-(4- piperidinobutoxy)pyrimidine is exemplified as the compound of formula I. The compound of formula I is obtained by reacting a compound of formula II (Q is a halogen) with a compound of formula III in the presence of a base (e.g. NaOH) in a solvent (e.g. DMF) at 0-140 deg.C.  The compound is capable of manifesting excellent suppressing actions on neuron necrosis, especially in the acute period of cerebral angiopathy and useful for suppressing the onset of the cerebral angiopathy and a sequela thereto.
PURPOSE:To improve the emulsified state of an emulsified compsn. and the stability over a long period by blending an adduct of polyoxyethylene to &gt;=22C higher alcohol with lower alcohol and an oil component to prepare the emulsified compsn. CONSTITUTION:The adduct of polyoxyethylene to &gt;=22C higher alcohol is blended with lower alcohol and the oil component or further blended with additives such as a thickener, an org. pigment and a fungicide to prepare an emulsified compsn. the higher alcohol may be behenyl alcohol or carnaubyl alcohol and about 1-30mol polyoxyethylene is preferably added to the higher alcohol. The lower alcohol is &lt;=5C alcohol and the pref. amt. of the lower alcohol used is 5-40wt.%. The oil component may be selected among fats, oils, waxes and hydrocarbons and the pref. amt. of the oil component used is 0.5-80wt.%.
Glioblastoma multiforme (GBM) is an aggressive form of brain cancer. Biomarkers for GBM that provide prognostic and predictive information are useful because they provide the physician valuable information regarding treatment options for GBM. The present invention provides a method to quantify such biomarkers. Thus, the method relates to the quantification of GSK3β, S6, CREB, PTEN, AKT and mTOR biomarkers and the use of AQUA® analysis to estimate a patient&#39;s risk and benefit to treatment using an inhibitor of the AGC-family kinase. Unlike traditional IHC, the AQUA® system is objective and produces quantitative in situ protein expression data on a continuous scale. The present invention uses the AQUA system to provide a robust and standardized diagnostic assay that can be used in a clinical setting to provide prognostic and predictive information.
PURPOSE:To separate blood components such as erythrocyte, leukocyte, thrombocyte, etc., from whole blood in high efficiency without fear of ATLA infection, by using a specific process. CONSTITUTION:Blood is fractionated to an oligothrombocytic plasma A constituting an upper layer, a liquid mixture B of thrombocyte and leukocyte constituting the intermediate layer and a concentrated erythrocyte liquid C constituting the lower layer, by strong centrifugal treatment. The concentrated erythrocyte liquid C is diluted with a part of the oligothrombocytic plasma A to correct the hematocrit value of he concentrated erythrocyte liquid to &lt;=80% and the mixed liquid B is subjected to weak centrifugal treatment and fractionated into a lower leukocyte layer and an upper concentrated thrombocyte layer. The strong centrifugal treatment is carried out at 1,700-5,500G for 4-10min to separate the solution into an oligothrombocytic plasma layer, a thrombocyte layer, a leukocyte layer and a concentrated erythrocyte liquid layer from the top downward. The weak centrifugal treatment is carried out at 700-600G for 4-10min and the thrombocyte can be easily separated from the leukocyte. EFFECT:The factor VIII can be obtained as a highly concentrated preparation having decreased side effect in high yield.
A method for managing a dental work flow using digital automation. After a remote consultation, the patient is sent a portable scanning wand or device by a dental professional. The patient performs a self intra-oral scan as directed and then transmits the video over a network such as the internet. Before the dental professional can review the transmitted data, a data management module analyzes the transmitted video using a suite of artificial intelligence (AI) tools and automatically prepares an original report or summary which details any likely issues present within the patient&#39;s teeth. An additional supplemental report may also be generated by the suite of AI tools which lists any required treatments, any possible elective treatments, and any further treatment options that may be provided responsively to the patient. The dental professional can then form a diagnosis for the patient and then send the diagnosis directly to the patient.
An access port for transporting fluids into a patient&#39;s body utilizing a multiple seals in parallel is disclosed. The access port 100 includes a flanged base 102, a receptacle 106 with multiple seals 108 and 110, and a cannula 104. The access port may also include a guide needle for installation purposes, and a sanitary adaptor that seals the receptacle for long term usage. Adhesives or bandaging may utilize the flanged base to secure the access port to the patient. The flanged base may also be installed beneath the patient&#39;s skin so secure the access port. The receptacle utilizes a multitude of sealing mechanism, including but not limited to O-ring seals and screw-lock seals. The receptacle additionally contains and outlet flow path leading to the cannula. The cannula connects from the receptacle into the patient&#39;s body. The cannula is installed perpendicular to the plane of the flanged base and protrudes on the side of the access port facing into the patient&#39;s body while the receptacle faces outward. A number of devices may work in conjunction to access port 100 that interface with the multiple parallel seal mechanism. Guide needle 200 may be utilized during installation, sanitary seal 300 may be used for long term use, and band 500 in conjunction with bag 600 may be worn on a patient to deliver substances into their body. Programmable components 512, 606, and 712 may be implemented with these devices that enables a system that automatically identifies the substance being administered and dosing information, then relays that information to a doctor or caregiver.
The utility model relates to a bigeminal capsule, particularly a novel preparation which comprises peroral medicines respectively in different capsule chambers in the same capsule and belongs to the field of medicine preparations. The preparation is composed of a normal capsule and capsule caps, wherein the normal capsule is externally sheathed with the capsule caps to form the two capsule chambers; the normal capsule and the capsule caps can be respectively gastrically dissolved and/or enterically dissolved capsules. Thus, a gastrically dissolved and gastrically dissolved capsule and an enterically dissolved and enterically dissolved capsule are respectively formed. A gastrically dissolved capsule cap is dissolved in a stomach to release the medicines into the stomach; an enterically dissolved capsule cap is dissolved in an intestinal tract to release the medicines into the intestinal tract. The same medicines and different preparations and different medicines or different medicine preparations can be placed in the two capsule chambers. The preparation can avoid the occurrence of the interaction of the medicines outside a body, extend the period of validity of the medicines and reduce medicine failure caused by the interaction among compound medicines. The utility model is favorable for making medicines with unstable physicochemical properties into compound preparations, which facilitates a quality analysis. Thus, clinical medicine combination is convenient, which improves patients&#39;compliance.
&lt;P&gt;PROBLEM TO BE SOLVED: To solve the problems that a buffer solution is added to povidone iodine (hereinafter, PVP-I) sugar and a PVP-I external preparation for adjusting pH, however, the buffer solution remains in the form of KI&lt;SB&gt;3&lt;/SB&gt;caused by the influence of sodium ions included in the buffer solution and the addition of KI, so the preparation has properties different from those of the original PVP-I; though PVP-I is slowly releasable in an aqueous solution, but it quickly releases iodine when there is an reactive object, so it is thought that it is fatal to generate cytotocicity and the like; PVP-I sugar for treating decubitus ulcers is a water-soluble substrate and it has high possibility of delaying the healing of an injured area as it has the tendency to dry the injured area; and the like.  &lt;P&gt;SOLUTION: A water-in-oil emulsion substrate is used to avoid direct contact of PVP-I to skin cell tissue without using buffer or the like. As a result, sodium hyaluronate, gelatin or a derivative of the same used as a humectant is used for satisfying surface activity. By using gelatin, an external pressure is reduced. Sodium hydrogen carbonate (hereinafter, sodium bicarbonate) may be added to an oil layer for adjusting pH. In this case, PVP-I and sodium bicarbonate in a water layer do not mutually interfere, therefore, the preparation can be faithful to the original PVP-I. As described above, the stimulation to the skin has been chemically and physically improved.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT